The LXO Ambition

Since 2015, we have been specializing in the use of mature MAs in diverse therapeutic areas such as cardiology, central nervous system and internal medicine.and inter

A dynamic French pharmaceutical company with a human dimension, our growth is fuelled by the success of our brands, our international expansion and our strategy of external acquisitions. In a short period of 8 years, we have become one of the top third of French laboratories in terms of sales, and our ambition is to triple our sales within 5 years.


Laboratoire XO is also a committed laboratory:

We are committed to systematically favoring French or European production. In fact, 85% of our production is based in Europe, and 60% in France;

We are GDP-certified by ANSM, certified in Medical Visits and Ecocert-certified.


We entered a new phase of our growth in 2022 with the support of Stanley Capital. This European fund is committed alongside us to a dynamic acquisition strategy in Europe, with substantial additional financing already in place.

Stanley Capital Partners LLP (SCP), founded in 2019, is a fast-growing middle-market private equity firm focused on Europe.

With visions of creating value through M&A, operational change and technology activation, SCP offers increased efficiency through proprietary research and technology to identify investment opportunities. These contribute to sustainable transformation in the healthcare, resource efficiency and technology sectors, with enterprise values ranging from $250 million to $2.5 billion.

Karine Pinon

Co-founder & CEO - LXO Group

Peter Burema

Non Executive Director - Stanley Capital

Yair Erez

Partner - Stanley Captial

Patrick Hargutt

Founding Partner - Stanley Capital

Simon Cottle

Founding Partner - Stanley Capital

We are present in more than 80 countries around the world, with a responsive distribution network close to local needs.

Our offices are located in Saint-Cloud (France), Dublin (Ireland) and Lansdale (United States).